

# Philip S Helliwell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4385667/publications.pdf>

Version: 2024-02-01

215  
papers

12,619  
citations

43973

48  
h-index

27345

106  
g-index

232  
all docs

232  
docs citations

232  
times ranked

6661  
citing authors

#	ARTICLE	IF	CITATIONS
1	Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. <i>Arthritis and Rheumatism</i> , 2006, 54, 2665-2673.	6.7	2,811
2	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	2.9	726
3	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
4	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.5	397
5	Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 2489-2498.	6.3	389
6	Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 686-691.	6.7	339
7	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1012-1019.	0.5	314
8	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 986-991.	0.5	240
9	Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNF $\alpha$ inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1115-1125.	6.3	211
10	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 123-131.	0.5	206
11	Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. <i>Arthritis Care and Research</i> , 2010, 62, 965-969.	1.5	201
12	Psoriatic arthritis: state of the art review. <i>Clinical Medicine</i> , 2017, 17, 65-70.	0.8	198
13	Development of a preliminary composite disease activity index in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 272-277.	0.5	184
14	Assessment of patients with psoriatic arthritis: A review of currently available measures. <i>Arthritis and Rheumatism</i> , 2004, 50, 24-35.	6.7	171
15	Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1112-1124.	2.9	164
16	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018, 392, 2367-2377.	6.3	159
17	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1167-70.	1.0	155
18	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015, 6, 6046.	5.8	149

#	ARTICLE	IF	CITATIONS
19	Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>Rheumatology and Therapy</i> , 2016, 3, 91-102.	1.1	146
20	A randomized controlled trial of foot orthoses in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002, 29, 1377-83.	1.0	134
21	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 291-304.	1.6	119
22	Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases. <i>Dermatology and Therapy</i> , 2013, 3, 1-15.	1.4	106
23	The impact of rheumatoid arthritis on foot function in the early stages of disease: a clinical case series. <i>BMC Musculoskeletal Disorders</i> , 2006, 7, 102.	0.8	104
24	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1235-1242.	6.7	104
25	Development of a foot impact scale for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 53, 418-422.	6.7	103
26	Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study. <i>Journal of Rheumatology</i> , 2011, 38, 898-903.	1.0	101
27	Development of an assessment tool for dactylitis in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1745-50.	1.0	100
28	A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 575-584.	1.6	90
29	The TICOPA protocol (Tight Control of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 101.	0.8	89
30	Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study. <i>Journal of Rheumatology</i> , 2016, 43, 356-361.	1.0	89
31	Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments. <i>Journal of Rheumatology</i> , 2016, 43, 371-375.	1.0	87
32	Sensitivity and specificity of the Classification of Psoriatic Arthritis criteria in early psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3150-3155.	6.7	84
33	Tofacitinib for the treatment of psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 719-730.	1.3	83
34	Is There Subclinical Synovitis in Early Psoriatic Arthritis? A Clinical Comparison With Grayâ€Scale and Power Doppler Ultrasound. <i>Arthritis Care and Research</i> , 2014, 66, 432-439.	1.5	79
35	Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 185-193.	0.5	79
36	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. <i>Journal of Rheumatology</i> , 2007, 34, 1740-5.	1.0	74

#	ARTICLE	IF	CITATIONS
37	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1759-1766.	1.5	73
38	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	2.9	72
39	Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. <i>Arthritis Care and Research</i> , 2016, 68, 267-274.	1.5	69
40	Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. <i>Rheumatology</i> , 2015, 54, 157-162.	0.9	66
41	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1882-1885.	0.5	64
42	Brief Report: Reduced Joint Counts Misclassify Patients With Oligoarticular Psoriatic Arthritis and Miss Significant Numbers of Patients With Active Disease. <i>Arthritis and Rheumatism</i> , 2013, 65, 1504-1509.	6.7	60
43	Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 358-362.	0.5	57
44	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. <i>Journal of Rheumatology</i> , 2007, 34, 1733-9.	1.0	57
45	Comparison of Composite Measures of Disease Activity in Psoriatic Arthritis Using Data From an Interventional Study With Golimumab. <i>Arthritis Care and Research</i> , 2014, 66, 749-756.	1.5	56
46	Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 649-655.	0.6	55
47	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. <i>Lancet Rheumatology</i> , The, 2021, 3, e715-e723.	2.2	53
48	Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2014, 41, 2277-2285.	1.0	51
49	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	1.6	50
50	Measuring dactylitis in clinical trials: which is the best instrument to use?. <i>Journal of Rheumatology</i> , 2007, 34, 1302-6.	1.0	50
51	Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs – comparison of drugs and adverse reactions. <i>Journal of Rheumatology</i> , 2008, 35, 472-6.	1.0	49
52	Psoriatic Arthritis Spondylitis Radiology Index: A Modified Index for Radiologic Assessment of Axial Involvement in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 1006-1011.	1.0	47
53	Fatigue in psoriatic arthritis—A cross-sectional study of 246 patients from 13 countries. <i>Joint Bone Spine</i> , 2016, 83, 439-443.	0.8	47
54	Comprehensive Treatment of Dactylitis in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2295-2300.	1.0	45

#	ARTICLE	IF	CITATIONS
55	Pathophysiology, assessment and treatment of psoriatic dactylitis. <i>Nature Reviews Rheumatology</i> , 2019, 15, 113-122.	3.5	45
56	Assessing Disease Activity in Psoriatic Arthritis: A Literature Review. <i>Rheumatology and Therapy</i> , 2019, 6, 23-32.	1.1	43
57	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B*27 Status?. <i>Arthritis Care and Research</i> , 2021, 73, 856-860.	1.5	43
58	Foot orthoses in the treatment of symptomatic midfoot osteoarthritis using clinical and biomechanical outcomes: a randomised feasibility study. <i>Clinical Rheumatology</i> , 2016, 35, 987-996.	1.0	41
59	Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNF± inhibitor-experienced. <i>RMD Open</i> , 2021, 7, e001457.	1.8	41
60	Classification of the spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 2005, 17, 395-399.	2.0	38
61	Treating to target in psoriatic arthritis: how to implement in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 640-643.	0.5	38
62	Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. <i>RMD Open</i> , 2020, 6, e001149.	1.8	38
63	Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis. <i>Rheumatology and Therapy</i> , 2015, 2, 1-16.	1.1	37
64	Outcome measures in psoriatic arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 2262-9.	1.0	37
65	Problems with the definition of axial and peripheral disease patterns in psoriatic arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 974-7.	1.0	36
66	Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) – Report of the OMERACT 10 PsA Special Interest Group. <i>Journal of Rheumatology</i> , 2011, 38, 1496-1501.	1.0	35
67	Patient global assessment in psoriatic arthritis – what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. <i>Joint Bone Spine</i> , 2016, 83, 335-340.	0.8	35
68	Development of Screening Tools to Identify Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2010, 12, 295-299.	2.1	34
69	Development of a Disease Activity and Responder Index for Psoriatic Arthritis – Report of the Psoriatic Arthritis Module at OMERACT 11. <i>Journal of Rheumatology</i> , 2014, 41, 782-791.	1.0	34
70	Patient Involvement in Outcome Measures for Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 418.	2.1	34
71	Enhanced Patient Involvement and the Need to Revise the Core Set – Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015, 42, 2198-2203.	1.0	34
72	Therapies for dactylitis in psoriatic arthritis. A systematic review. <i>Journal of Rheumatology</i> , 2006, 33, 1439-41.	1.0	34

#	ARTICLE	IF	CITATIONS
73	Debridement of painful forefoot plantar callosities in rheumatoid arthritis: the CARROT randomised controlled trial. <i>Clinical Rheumatology</i> , 2013, 32, 567-574.	1.0	33
74	Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review. <i>Journal of Rheumatology</i> , 2008, 35, 1438-42.	1.0	33
75	It's not just the joints, it's the whole thing: qualitative analysis of patients' experience of flare in psoriatic arthritis. <i>Rheumatology</i> , 2015, 54, 1448-1453.	0.9	32
76	Disease measurement "enthesitis, skin, nails, spine and dactylitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 659-670.	1.4	31
77	Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). <i>Rheumatology</i> , 2020, 59, 2774-2784.	0.9	31
78	Psoriasis Epidemiology Screening Tool (PEST): A Report from the GRAPPA 2009 Annual Meeting. <i>Journal of Rheumatology</i> , 2011, 38, 551-552.	1.0	30
79	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110579.	1.2	30
80	Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. <i>Arthritis Care and Research</i> , 2018, 70, 1198-1205.	1.5	29
81	Dactylitis: Pathogenesis and clinical considerations. <i>Current Rheumatology Reports</i> , 2006, 8, 338-341.	2.1	27
82	Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. <i>RMD Open</i> , 2022, 8, e002074.	1.8	27
83	Current concepts and unmet needs in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 297-305.	1.0	26
84	Assessment of disease activity in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S44-7.	0.4	26
85	Comparison of screening questionnaires to identify psoriatic arthritis in a primary-care population: a cross-sectional study. <i>British Journal of Dermatology</i> , 2016, 175, 542-548.	1.4	25
86	Development of Criteria to Distinguish Inflammatory from Noninflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1249-1251.	1.0	24
87	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 965-969.	1.0	24
88	Modification of the Psoriatic Arthritis Disease Activity Score (PASDAS). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 467-468.	0.5	24
89	Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. <i>Arthritis Research and Therapy</i> , 2018, 20, 242.	1.6	24
90	Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity. <i>BMC Rheumatology</i> , 2018, 2, 24.	0.6	24

#	ARTICLE	IF	CITATIONS
91	What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?. <i>Journal of Rheumatology</i> , 2019, 46, 38-42.	1.0	24
92	Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e001486.	1.8	24
93	Axial disease in psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, 1193-1195.	0.9	23
94	Relationship of psoriatic arthritis with the other spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 2004, 16, 344-349.	2.0	22
95	Use of conservative and surgical foot care in an inception cohort of patients with rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 1586-1595.	0.9	22
96	Composite Measures in Psoriatic Arthritis: A Report from the GRAPPA 2009 Annual Meeting. <i>Journal of Rheumatology</i> , 2011, 38, 540-545.	1.0	22
97	Clinical Examination, Ultrasound and MRI Imaging of The Painful Elbow in Psoriatic Arthritis and Rheumatoid Arthritis: Which is Better, Ultrasound or MR, for Imaging Enthesitis?. <i>Rheumatology and Therapy</i> , 2017, 4, 71-84.	1.1	22
98	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. <i>Arthritis Care and Research</i> , 2014, 66, 1410-1416.	1.5	21
99	The Diagnosis and Treatment of Adult Patients with SAPHO Syndrome: Controversies Revealed in a Multidisciplinary International Survey of Physicians. <i>Rheumatology and Therapy</i> , 2020, 7, 883-891.	1.1	21
100	Development of diagnostic criteria for psoriatic arthritis: Methods and process. <i>Current Rheumatology Reports</i> , 2004, 6, 299-305.	2.1	20
101	The predictors of foot ulceration in patients with rheumatoid arthritis: a preliminary investigation. <i>Clinical Rheumatology</i> , 2008, 27, 1423-1428.	1.0	20
102	A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis		

#	ARTICLE	IF	CITATIONS
109	Methodological considerations for a randomised controlled trial of podiatry care in rheumatoid arthritis: lessons from an exploratory trial. <i>BMC Musculoskeletal Disorders</i> , 2007, 8, 109.	0.8	18
110	Established Psoriatic Arthritis: Clinical Aspects. <i>Journal of rheumatology Supplement, The</i> , 2009, 83, 21-23.	2.2	18
111	A case series to describe the clinical characteristics of foot ulceration in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2012, 31, 541-545.	1.0	18
112	Benchmarking Care in Psoriatic Arthritis – The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 674-678.	1.0	18
113	Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients. <i>Rheumatology and Therapy</i> , 2019, 6, 521-528.	1.1	18
114	The dynamics of response as measured by multiple composite outcome tools in the Tight Control of inflammation in early Psoriatic Arthritis (TICOPA) trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1688-1692.	0.5	17
115	The Composite DAS Score is Impractical to use in Daily Practice. <i>Journal of Clinical Rheumatology</i> , 2009, 15, 223-225.	0.5	16
116	The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome. <i>Rheumatology</i> , 2016, 55, 2277-2278.	0.9	16
117	The predictors of foot ulceration in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2014, 33, 615-621.	1.0	15
118	Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2014, 383, S36.	6.3	15
119	Treat to Target in Psoriatic Arthritis – Evidence, Target, Research Agenda. <i>Current Rheumatology Reports</i> , 2015, 17, 517.	2.1	15
120	Psoriasis flare with corticosteroid use in psoriatic arthritis. <i>British Journal of Dermatology</i> , 2016, 174, 219-221.	1.4	15
121	Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. <i>Arthritis and Rheumatology</i> , 2022, 74, 1535-1543.	2.9	15
122	Magnetic Resonance Arthrography of Lesser Metatarsophalangeal Joints in Patients with Rheumatoid Arthritis: Relationship to Clinical, Biomechanical, and Radiographic Variables. <i>Journal of Rheumatology</i> , 2012, 39, 1786-1791.	1.0	14
123	Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 1700-1705.	1.5	14
124	Focussing on the foot in psoriatic arthritis: pathology and management options. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 21-28.	1.3	14
125	Remission in Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2012, 89, 19-21.	2.2	13
126	Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 974-978.	1.0	13



#	ARTICLE	IF	CITATIONS
127	Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity. <i>Arthritis Care and Research</i> , 2018, 70, 797-800.	1.5	13
128	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 1137-1147.	0.9	13
129	Developing classification criteria for peripheral joint psoriatic arthritis. Step I. Establishing whether the rheumatologist's opinion on the diagnosis can be used as the "gold standard". <i>Journal of Rheumatology</i> , 2006, 33, 552-7.	1.0	13
130	Classification and categorisation of psoriatic arthritis. <i>Clinical Rheumatology</i> , 2008, 27, 1211-1216.	1.0	12
131	Cost-Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2018, 70, 462-468.	1.5	12
132	Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1530-1534.	1.3	11
133	Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. <i>Arthritis Care and Research</i> , 2020, 72, 1579-1588.	1.5	11
134	The definition of remission in psoriatic arthritis: can this be accurate without assessment of multiple domains?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e66-e66.	0.5	10
135	Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. <i>Journal of Rheumatology</i> , 2018, 45, 1256-1262.	1.0	10
136	Assessment of Enthesitis in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 869-870.	1.0	10
137	Comparing Psoriatic Arthritis Low-field Magnetic Resonance Imaging, Ultrasound, and Clinical Outcomes: Data from the TICOPA Trial. <i>Journal of Rheumatology</i> , 2020, 47, 1338-1343.	1.0	10
138	Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naïve early psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 490-495.	0.5	10
139	A discrete choice experiment to explore patients' willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2967-2974.	1.0	9
140	Replication of a distinct psoriatic arthritis risk variant at the IL23R locus. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1417-1418.	0.5	9
141	The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 303.	0.8	9
142	Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. <i>Arthritis Research and Therapy</i> , 2021, 23, 94.	1.6	9
143	Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. <i>Journal of Rheumatology</i> , 2021, , jrheum.201674.	1.0	9
144	GRAPPA Responder Index Project (GRACE): A Report from the GRAPPA 2011 Annual Meeting. <i>Journal of Rheumatology</i> , 2012, 39, 2196-2197.	1.0	8

#	ARTICLE	IF	CITATIONS
145	Screening psoriatic arthritis tools: analysis of the Early Arthritis for Psoriatic Patients questionnaire. <i>Rheumatology</i> , 2015, 54, 200-202.	0.9	8
146	Long-term follow-up of patients in the Tight COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. <i>Rheumatology</i> , 2020, 59, 807-810.	0.9	8
147	Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201672.	1.0	8
148	Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial. <i>Lancet Rheumatology, The</i> , 2022, 4, e252-e261.	2.2	8
149	Psoriasis and Psoriatic Arthritis Educational Initiatives: An Update from the 2013 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1240-1243.	1.0	7
150	Plantar plate pathology is associated with erosive disease in the painful forefoot of patients with rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 308.	0.8	7
151	Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. <i>ACR Open Rheumatology</i> , 2020, 2, 543-554.	0.9	7
152	Patient Reported Outcomes in Chronic Inflammatory Diseases: Current State, Limitations and Perspectives. <i>Frontiers in Immunology</i> , 2021, 12, 614653.	2.2	7
153	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , 2019, 95, 54-57.	1.0	7
154	GRAPPA 2019 Project Report. <i>Journal of Rheumatology</i> , 2020, 96, 53-57.	1.0	7
155	Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). <i>Trials</i> , 2020, 21, 155.	0.7	6
156	A clinical and radiographic comparison of patients with psoriatic arthritis from different ethnic backgrounds. <i>Rheumatology</i> , 2021, 60, 340-345.	0.9	6
157	The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. <i>Rheumatology</i> , 2022, 61, e255-e266.	0.9	6
158	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. <i>Rheumatology</i> , 2023, 62, 606-616.	0.9	6
159	GRAPPA 2013 Annual Meeting, Rheumatology Updates: Psoriatic Arthritis (PsA) Biomarker Project, Arthritis Mutilans, PsA-Peripheral Spondyloarthritis Epidemiology Project. <i>Journal of Rheumatology</i> , 2014, 41, 1244-1248.	1.0	5
160	Diurnal variation of gait in patients with rheumatoid arthritis: The DIVIGN study. <i>Clinical Biomechanics</i> , 2014, 29, 811-814.	0.5	5
161	Interleukin-17 inhibition in psoriatic arthritis. <i>Lancet, The</i> , 2015, 386, 1114-1116.	6.3	5
162	Interpreting outcome following foot surgery in people with rheumatoid arthritis. <i>Journal of Foot and Ankle Research</i> , 2016, 9, 20.	0.7	5

#	ARTICLE	IF	CITATIONS
163	To Lump or Split When Assessing Psoriatic Arthritis “ Not Mutually Exclusive?. Journal of Rheumatology, 2020, 47, 307-309.	1.0	5
164	Best-practice Indicators in Psoriatic Disease Care. Journal of Rheumatology, 2019, 95, 38-45.	1.0	5
165	Comparing the Visual Analog Scale and the Numerical Rating Scale in Patient-reported Outcomes in Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, 836-840.	1.0	5
166	Comment on: Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology, 2010, 49, 1793-1794.	0.9	4
167	Joint Orthopaedic and Rheumatology Clinics: Evidence to Support the Guidelines. Musculoskeletal Care, 2011, 9, 180-183.	0.6	4
168	Screening for Psoriatic Arthritis in People with Psoriasis. Journal of Rheumatology, 2015, 42, 736-738.	1.0	4
169	Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. Journal of Rheumatology, 2021, 48, 1268-1271.	1.0	4
170	Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis Research and Therapy, 2022, 24, 40.	1.6	4
171	Treat-to-target in psoriatic arthritis“ cost-effective in the biosimilar era. Lancet Rheumatology, The, 2022, 4, e390-e391.	2.2	4
172	Human nocturnal blood melatonin and liver acetylation status. Journal of Pineal Research, 1991, 10, 14-17.	3.4	3
173	GRAPPA 2015 Research and Education Project Reports. Journal of Rheumatology, 2016, 43, 979-985.	1.0	3
174	Verna Wright: father of the spondyloarthropathies. Annals of the Rheumatic Diseases, 2019, 78, 454-455.	0.5	3
175	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. Rheumatology Advances in Practice, 2020, 4, rkaa032.	0.3	3
176	Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study. Journal of Rheumatology, 2021, , jrheum.201675.	1.0	3
177	Pustular Psoriasis and Associated Musculoskeletal Disorders. Journal of Rheumatology, 2021, , jrheum.201673.	1.0	3
178	Correspondence on “No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related “ physician-reported spondylitis“™?™. Annals of the Rheumatic Diseases, 2023, 82, e187-e187.	0.5	3
179	Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study. Patient, 0, , .	1.1	3
180	Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: Comment on the article by Clegg et al. Arthritis and Rheumatism, 1997, 40, 1911-1912.	6.7	2

#	ARTICLE	IF	CITATIONS
181	Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015, 42, 1041-1043.	1.0	2
182	Presidential Round Table: A Report from the GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 986-989.	1.0	2
183	GRAPPA 2016 Project Report. <i>Journal of Rheumatology</i> , 2017, 44, 706-710.	1.0	2
184	Werner syndrome: a rare cause of osteoporosis in a young female. <i>Rheumatology</i> , 2018, 57, 2021-2021.	0.9	2
185	The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register. <i>BMC Rheumatology</i> , 2021, 5, 19.	0.6	2
186	Aiming for remission in psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 147-153.	0.3	1
187	The NICE appraisal of ustekinumab for treating psoriatic arthritis. <i>British Journal of Health Care Management</i> , 2016, 22, 68-71.	0.1	1
188	An educational leaflet improves response to invitation for screening for arthritis in patients with psoriasis in primary care, but only in practices in the most deprived areas. <i>Clinical Rheumatology</i> , 2017, 36, 719-723.	1.0	1
189	AB0742â€¦ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS. , 2019, , .		1
190	P262â€¦Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNF± inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study. <i>Rheumatology</i> , 2020, 59, .	0.9	1
191	P174â€¦Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. <i>Rheumatology</i> , 2021, 60, .	0.9	1
192	Measuring Physical Function in Psoriatic Arthritis: Comparing the Multidimensional Health Assessment Questionnaire to the Health Assessment Questionnaireâ€¦Disability Index. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.200927.	1.0	1
193	Molecular and cellular regulation of psoriatic inflammation. <i>Clinical Science</i> , 2022, 136, 935-952.	1.8	1
194	Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. <i>Rheumatology</i> , 0, , .	0.9	1
195	Biomechanics of the foot in rheumatoid arthritis: Identifying abnormal function and the factors that predict disease impact. <i>Clinical Biomechanics</i> , 2008, 23, 719-720.	0.5	0
196	The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Disease Index Project (GRACE). <i>Psoriasis Forum</i> , 2011, 17a, 216-219.	0.1	0
197	I58.â€¦Therapy of PSA: What is New and How Can We Treat to Target?. <i>Rheumatology</i> , 2014, 53, i13-i13.	0.9	0
198	177.â€¦Mechanical Factors that May Contribute to Toe Dactylitis in Patients with Psoriatic Arthritis. <i>Rheumatology</i> , 2014, 53, i125-i126.	0.9	0

#	ARTICLE	IF	CITATIONS
199	179.â€fFoot Orthoses in the Treatment of Symptomatic Midfoot Osteoarthritis Using Clinical and Biomechanical Outcomes: A Feasibility Study. <i>Rheumatology</i> , 2014, 53, i126-i126.	0.9	0
200	I58â€fPsoriatic Arthritis: Anti-Tumour Necrosis Factor and Beyond. <i>Rheumatology</i> , 0, , .	0.9	0
201	I111â€fStrategies for the Use of Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis, Including Treat to Target. <i>Rheumatology</i> , 0, , .	0.9	0
202	More than meets the eye?. <i>Lancet, The</i> , 2016, 388, e15.	6.3	0
203	L.C. Coates and P.S. Helliwell reply. <i>Journal of Rheumatology</i> , 2016, 43, 1766.2-1766.	1.0	0
204	Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?. <i>Clinical Rheumatology</i> , 2017, 36, 1803-1810.	1.0	0
205	O69.â€fCONSTRUCT VALIDITY, RESPONSIVENESS AND MINIMALLY IMPORTANT DIFFERENCE OF THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 IN PSORIATIC ARTHRITIS. <i>Rheumatology</i> , 2017, 56, .	0.9	0
206	A new era for collaboration?. <i>Rheumatology</i> , 2018, 57, 775-776.	0.9	0
207	AB0745â€f...ASSESSMENT OF DISEASE ACTIVITY USING RAPID3 AND EVALUATION OF TREATMENT EFFECT OF GUSELKUMAB IN PATIENTS WITH PSA: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL. , 2019, , .		0
208	SAT0387â€f...CONSISTENT EFFICACY IN PATIENT SUBGROUPS ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS: RESULTS FROM A PHASE 2 STUDY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. , 2019, , .		0
209	BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa043.	0.3	0
210	P277â€fAssessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial. <i>Rheumatology</i> , 2020, 59, .	0.9	0
211	GRAPPA 2020 Update From the Education Committee. <i>Journal of Rheumatology</i> , 2021, , jrheum.201678.	1.0	0
212	P172â€fQuality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment. <i>Rheumatology</i> , 2021, 60, .	0.9	0
213	Development of an Instrument for Patient Self-assessment in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.210010.	1.0	0
214	Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores. <i>Clinical Trials</i> , 2021, 18, 541-551.	0.7	0
215	2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. <i>Journal of Rheumatology</i> , 2022, , .	1.0	0